A clinical study getting underway in Rotorua and Christchurch will provide valuable information on how our the population responds to the Pfizer-BioNTech Covid-19 vaccine.
The study aims to enrol at least 300 adult participants with a focus on Maori, Pasifika, adults 65 years old and older, and those with co-morbidities associated with increased risk of Covid-19.
The study will assess immune responses for up to 12 months after the last vaccine dose.
Sela Jane Hopgood delves into what the study entails.
